Fineline Cube

Follow:
14415 Articles
Jiangsu Hengrui's SHR-A2102 Earns Breakthrough Therapy Designation for Urothelial Carcinoma
CompanyDrug

Jiangsu Hengrui’s SHR-A2102 Earns Breakthrough Therapy Designation for Urothelial Carcinoma

Roche's Columvi Supplemental sBLA Accepted by FDA for Relapsed DLBCL Treatment
CompanyDrug

Roche’s Columvi Supplemental sBLA Accepted by FDA for Relapsed DLBCL Treatment

Teva Pharmaceutical to Divest Holdings in Teva Takeda Pharma to JKI
CompanyDrug

Teva Pharmaceutical to Divest Holdings in Teva Takeda Pharma to JKI

Eyebright Medical Technology Aims to Raise RMB 300 Million for Contact Lens Production Expansion
CompanyDeals

Eyebright Medical Technology Aims to Raise RMB 300 Million for Contact Lens Production Expansion

Cambrex Partners with Eli Lilly to Enhance Clinical Development for Biotech Collaborators
CompanyDeals

Cambrex Partners with Eli Lilly to Enhance Clinical Development for Biotech Collaborators

Dewpoint Therapeutics Partners with Mitsubishi Tanabe Pharma to Develop ALS Treatment
CompanyDeals

Dewpoint Therapeutics Partners with Mitsubishi Tanabe Pharma to Develop ALS Treatment

AstraZeneca's Imfinzi Receives FDA Approval for Limited-Stage Small Cell Lung Cancer
CompanyDrug

AstraZeneca’s Imfinzi Receives FDA Approval for Limited-Stage Small Cell Lung Cancer

Eli Lilly & Co. Expands Wisconsin Manufacturing Facility with $3 Billion Investment
Company

Eli Lilly & Co. Expands Wisconsin Manufacturing Facility with $3 Billion Investment

Amgen Expands Biomanufacturing Footprint in North Carolina with Second Facility
Company

Amgen Expands Biomanufacturing Footprint in North Carolina with Second Facility

Merck Initiates Phase III MOVE-NOW Study for Lagevrio COVID-19 Antiviral
CompanyDrug

Merck Initiates Phase III MOVE-NOW Study for Lagevrio COVID-19 Antiviral

CDE Approves RinuaGene's mRNA-Based RG002 for Clinical Study in Cervical Dysplasia
CompanyDrug

CDE Approves RinuaGene’s mRNA-Based RG002 for Clinical Study in Cervical Dysplasia

Burning Rock Ltd Reports Q3 2024 Financials with Revenue Growth and R&D Reduction
Company

Burning Rock Ltd Reports Q3 2024 Financials with Revenue Growth and R&D Reduction